Dr. Manchanda has been named Chief Development Officer after serving as Anokion’s Chief Technical Operations Officer (CTOO). Raj brings over 23 years of pharmaceutics development and program management experience to Anokion and most recently was Innovation Portfolio Leader at the Bill & Melinda Gates Medical Research Institute. Previously, he was Chief Development Officer at Frequency Therapeutics where he had oversight of drug development and manufacturing, portfolio and project management, infrastructure-building, and execution of global clinical development and regulatory strategy. Prior to Frequency, Raj was Vice President, Neurodegeneration and Early-Stage Therapeutics Asset Development at Biogen. While at Biogen, he was instrumental in leading the CMC development for approval and commercialization for Tecfidera™. Earlier in his career, Raj held leadership positions in at Diatide, Avid Radiopharmaceuticals, Perkin Elmer Life and Analytical Sciences and URL Pharmaceuticals. During his 23 years in the pharmaceutical industry, he has worked on over 25 INDs and 6 NDAs, including two drug development programs that received Fast Track designation from the U.S. Food and Drug Administration. Raj received his Ph.D. in Chemistry from Yale University and was an Anna Fuller postdoctoral fellow at MIT. Raj has also completed the Advanced Management Program from the Sloan School of Management at MIT.